Cytokinetics (CYTK) Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

14 brokerages have issued twelve-month target prices for Cytokinetics' shares. Their CYTK share price forecasts range from $42.00 to $80.00. On average, they anticipate the company's stock price to reach $58.21 in the next year. This suggests a possible upside of 116.6% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $45.82 on January 1st, 2023. Since then, CYTK stock has decreased by 41.3% and is now trading at $26.88.
View the best growth stocks for 2023 here.

Cytokinetics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 12,550,000 shares, an increase of 8.1% from the August 31st total of 11,610,000 shares. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 15.7 days. Currently, 13.7% of the company's stock are short sold.
View Cytokinetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.11. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $5.67 million. Cytokinetics's revenue was down 99.0% on a year-over-year basis. During the same period last year, the company posted ($0.23) EPS.

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED).

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $26.88.

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $2.58 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis.

The company employs 409 workers across the globe.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.